bbotx.comCrawled Nov 8, 2026
The company is a clinical-stage organization studying the role of RAS in cancer to advance drug discovery and development.
Redefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches.
BridgeBio Oncology Therapeutics emphasizes protecting the integrity and privacy of personal information collected online.
BridgeBio Oncology Therapeutics (BBOT) presents new clinical data for its KRASG12C inhibitor **BBO-8520**, emphasizing its combination with checkpoint inhibitors for **second-line+ KRASG12C inhibitor-experienced non-small cell lung cancer (NSCLC)** patients. The company also prioritizes exploring **BBO-11818** and **BBO-10203** combinations in **KRAS-mutant cancers**, advancing its pipeline in RAS-pathway malignancies.
Sep 2026BioSpaceNews article
BridgeBio Oncology Therapeutics discloses inducement grants awarded to executives and directors under Nasdaq’s Rule 5635(c)(4). The company, which develops oncology-focused therapies, files the required report as part of its Nasdaq-listed obligations. The grants align with standard equity compensation practices for publicly traded biotech firms.
Apr 2026GlobeNewswireNews article
BridgeBio Oncology Therapeutics is listing on Nasdaq through a SPAC merger. The move marks a notable biotech public offering in 2024, though specifics on the company’s pipeline or financial terms remain unstated.
Aug 2025Endpoints NewsNews article
BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company developing RAS and PI3Kα-targeting small molecule drugs, has agreed to merge with Helix Acquisition Corp. II, a SPAC backed by Cormorant Asset Management. The definitive business combination will combine BridgeBio’s oncology pipeline with Helix’s capital structure. The deal follows BridgeBio’s focus on novel therapeutics for RAS-driven malignancies.
Feb 2025citybizNews article
